Upstream Bio (UPB) to Release Earnings on Thursday

Upstream Bio (NASDAQ:UPB) is expected to be issuing its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of ($0.62) per share for the quarter.

Upstream Bio (NASDAQ:UPB) last posted its earnings results on Thursday, November 7th. The company reported ($6.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($6.38). The firm had revenue of $0.61 million for the quarter, compared to analyst estimates of $0.83 million. On average, analysts expect Upstream Bio to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Upstream Bio Stock Down 10.7 %

Shares of Upstream Bio stock opened at $8.87 on Wednesday. The company has a 50-day simple moving average of $16.20. Upstream Bio has a twelve month low of $8.36 and a twelve month high of $29.46.

Wall Street Analyst Weigh In

UPB has been the subject of several research analyst reports. Piper Sandler began coverage on Upstream Bio in a research note on Tuesday, November 5th. They set an “overweight” rating and a $75.00 target price for the company. TD Cowen initiated coverage on shares of Upstream Bio in a report on Tuesday, November 5th. They set a “buy” rating on the stock. JPMorgan Chase & Co. started coverage on shares of Upstream Bio in a research note on Tuesday, November 5th. They set an “overweight” rating and a $38.00 target price for the company. Finally, William Blair assumed coverage on shares of Upstream Bio in a research report on Tuesday, November 5th. They set an “outperform” rating for the company.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.